company background image
EEP

Euroespes BME:EEP Stock Report

Last Price

€0.53

Market Cap

€6.2m

7D

-1.9%

1Y

32.5%

Updated

04 Oct, 2022

Data

Company Financials
EEP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

EEP Stock Overview

Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally.

Euroespes Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Euroespes
Historical stock prices
Current Share Price€0.53
52 Week High€0.58
52 Week Low€0.39
Beta0.34
1 Month Change2.91%
3 Month Change1.92%
1 Year Change32.50%
3 Year Change-7.02%
5 Year Change-26.39%
Change since IPO-81.85%

Recent News & Updates

Nov 11
Would Euroespes (BME:EEP) Be Better Off With Less Debt?

Would Euroespes (BME:EEP) Be Better Off With Less Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

May 10
Here's Why Euroespes (BME:EEP) Can Afford Some Debt

Here's Why Euroespes (BME:EEP) Can Afford Some Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Shareholder Returns

EEPES Life SciencesES Market
7D-1.9%12.2%2.8%
1Y32.5%-32.3%-12.9%

Return vs Industry: EEP exceeded the Spanish Life Sciences industry which returned -34.3% over the past year.

Return vs Market: EEP exceeded the Spanish Market which returned -14.2% over the past year.

Price Volatility

Is EEP's price volatile compared to industry and market?
EEP volatility
EEP Average Weekly Movement2.5%
Life Sciences Industry Average Movement7.1%
Market Average Movement3.5%
10% most volatile stocks in ES Market6.3%
10% least volatile stocks in ES Market0.5%

Stable Share Price: EEP is not significantly more volatile than the rest of Spanish stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: EEP's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199141Ramon Cacabelos Garciahttps://www.euroespes.com

Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as digital diagnosis, neuro-psychology, neuro-otolaryngology, neuro-ophthalmology, nursing, radioa diagnosis, and laboratory services.

Euroespes Fundamentals Summary

How do Euroespes's earnings and revenue compare to its market cap?
EEP fundamental statistics
Market Cap€6.22m
Earnings (TTM)-€389.11k
Revenue (TTM)€3.24m

1.9x

P/S Ratio

-16.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EEP income statement (TTM)
Revenue€3.24m
Cost of Revenue€2.12m
Gross Profit€1.12m
Other Expenses€1.51m
Earnings-€389.11k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.033
Gross Margin34.50%
Net Profit Margin-11.99%
Debt/Equity Ratio55.6%

How did EEP perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is EEP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EEP?

Other financial metrics that can be useful for relative valuation.

EEP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA-47.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does EEP's PS Ratio compare to its peers?

EEP PS Ratio vs Peers
The above table shows the PS ratio for EEP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.7x
PANG Pangaea Oncology
6.2xn/a€41.5m
BST Biotechnology Assets
1.6xn/a€4.8m
RSCF Reflect Scientific
2.1xn/aUS$5.9m
511509 Vivo Bio Tech
1.1xn/a₹535.6m
EEP Euroespes
1.9xn/a€6.2m

Price-To-Sales vs Peers: EEP is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (2.7x).


Price to Earnings Ratio vs Industry

How does EEP's PE Ratio compare vs other companies in the European Life Sciences Industry?

Price-To-Sales vs Industry: EEP is good value based on its Price-To-Sales Ratio (1.9x) compared to the European Life Sciences industry average (4.4x)


Price to Sales Ratio vs Fair Ratio

What is EEP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EEP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate EEP's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of EEP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EEP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EEP's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Euroespes forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


13.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Euroespes has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of EEP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Euroespes competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Euroespes performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


65.1%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: EEP is currently unprofitable.

Growing Profit Margin: EEP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if EEP's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare EEP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EEP is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (16.3%).


Return on Equity

High ROE: EEP has a negative Return on Equity (-5.3%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Euroespes's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: EEP's short term assets (€2.8M) exceed its short term liabilities (€1.0M).

Long Term Liabilities: EEP's short term assets (€2.8M) do not cover its long term liabilities (€3.8M).


Debt to Equity History and Analysis

Debt Level: EEP's net debt to equity ratio (28.5%) is considered satisfactory.

Reducing Debt: EEP's debt to equity ratio has reduced from 70.9% to 55.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if EEP has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if EEP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Euroespes's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Euroespes Dividend Yield vs Market
How does Euroespes dividend yield compare to the market?
SegmentDividend Yield
Company (Euroespes)n/a
Market Bottom 25% (ES)2.3%
Market Top 25% (ES)6.2%
Industry Average (Life Sciences)0.6%
Analyst forecast in 3 Years (Euroespes)n/a

Notable Dividend: Unable to evaluate EEP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EEP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EEP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EEP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as EEP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Ramon Cacabelos Garcia

no data

Tenure

Mr. Ramon Cacabelos Garcia is President of the Board and Chief Executive Officer at Euroespes, S.A.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of EEP?
Owner TypeNumber of SharesOwnership Percentage

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.5%.

Company Information

Euroespes, S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Euroespes, S.A.
  • Ticker: EEP
  • Exchange: BME
  • Founded: 1991
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €6.215m
  • Shares outstanding: 11.73m
  • Website: https://www.euroespes.com

Number of Employees


Location

  • Euroespes, S.A.
  • Santa Marta de BabIo s / n
  • Bergondo
  • Corunna
  • Galicia
  • 15165
  • Spain


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EEPBME (Bolsas y Mercados Espanoles)YesShare CapitalESEURFeb 2011

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.